MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--Dec. 28, 2005--Perlegen Sciences, Inc. announced today a four-year research collaboration with Pfizer Inc for whole genome and replication studies that may identify genes associated with major diseases and predict patient responses to certain medicines. Researchers from both companies will conduct whole genome studies involving DNA samples from clinical trials. Pfizer and Perlegen scientists will design the research and analyze the results. Perlegen will conduct the genotyping, “reading” of the DNA, in the individual samples, using Affymetrix (Nasdaq:AFFX) GeneChip(R) technology. Under the terms of the agreement, Perlegen and Pfizer will share in certain intellectual property rights resulting from the collaboration. Pfizer will provide research payments to Perlegen.
